{"filing":{"accession_number":"0001171843-26-006229","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-09-25","report_date":"2026-09-24","primary_document":"f6k_092426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000117184326006229/f6k_092426.htm"},"events":[{"id":35005,"run_id":32235,"accession_number":"0001171843-26-006229","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing five-year follow-up clinical trial data for CARVYKTI (cilta-cel), Legend Biotech's lead therapeutic product. The disclosure presents material clinical efficacy and safety results from the CARTITUDE-2 Cohort A study, including a 50% progression-free survival rate at five years and 69.2% overall survival, which are significant outcomes for a cell therapy product. While this is not a financial earnings release in the traditional sense, it is a material clinical milestone announcement that would substantially affect investor assessment of the company's product pipeline and commercial prospects. The data directly supports the therapeutic potential and market value of the company's primary revenue-generating asset.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-25","form":"6-K","submitted_at":null,"items":[{"id":38919,"accession_number":"0001171843-26-006229","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing five-year follow-up clinical trial data for CARVYKTI (cilta-cel), Legend Biotech's lead therapeutic product. The disclosure presents material clinical efficacy and safety results from the CARTITUDE-2 Cohort A study, including a 50% progression-free survival rate at five years and 69.2% overall survival, which are significant outcomes for a cell therapy product. While this is not a financial earnings release in the traditional sense, it is a material clinical milestone announcement that would substantially affect investor assessment of the company's product pipeline and commercial prospects. The data directly supports the therapeutic potential and market value of the company's primary revenue-generating asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T11:00:48.774440+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38919,"accession_number":"0001171843-26-006229","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing five-year follow-up clinical trial data for CARVYKTI (cilta-cel), Legend Biotech's lead therapeutic product. The disclosure presents material clinical efficacy and safety results from the CARTITUDE-2 Cohort A study, including a 50% progression-free survival rate at five years and 69.2% overall survival, which are significant outcomes for a cell therapy product. While this is not a financial earnings release in the traditional sense, it is a material clinical milestone announcement that would substantially affect investor assessment of the company's product pipeline and commercial prospects. The data directly supports the therapeutic potential and market value of the company's primary revenue-generating asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T11:00:48.774440+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-25"}]}